Gestational exposure to antidepressants and the risk of spontaneous abortion: A review

Current Drug Delivery

Volumn 7, Issue 1, 2010, Pages 76-92

  Broy, Perrine ^b,c   Bérard, Anick ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c ENSAI Ecole Nationale de la Statistique et de lAnalyse de lInformation   (France)

Author keywords

Antidepressants; Pregnancy; Review; Spontaneous abortion

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; DOXEPIN; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ALCOHOL CONSUMPTION; CHRONIC DISEASE; COMORBIDITY; DRUG EXPOSURE; DRUG USE; FIRST TRIMESTER PREGNANCY; HUMAN; INFORMATION SERVICE; MATERNAL AGE; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; REVIEW; SPONTANEOUS ABORTION; TERATOGENICITY;

ABORTION, SPONTANEOUS; ANTIDEPRESSIVE AGENTS; FEMALE; HUMANS; MATERNAL EXPOSURE; PREGNANCY; TERATOGENS;

EID: 77949752910     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720110790396508     Document Type: Review

References (51)

1. Bennett, H.A.; Einarson A; Taddio A; Koren G; Einarson TR. Prevalence of depression during pregnancy: systematic review. Obstet. Gynecol., 2004, 103, 698-709.
2. Marcus, S.M.; Flynn HA; Blow FC; Barry KL. Depressive symptoms among pregnant women screened in obstetrics settings. J. Womens Health (Larchmt.), 2003, 12, 373-380.
3. Oberlander, T.F.; Warburton W; Misri S; Aghajanian J; Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch. Gen. Psychiatry, 2006, 63, 898-906.
4. Andersson, L.; Sundstrom-Poromaa, I.; Bixo, M.; Wulff, M.; Bondestam, K.; Strom, M. Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. Am. J. Obstet. Gynecol., 2003, 189, 148-154.
5. Gotlib, I.H.; Whiffen, V.E.; Mount, J.H.; Milne, K.; Cordy, N.I. Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum. J. Consult. Clin. Psychol., 1989, 57, 269-274.
6. Ramos, E.; Oraichi, D.; Rey, E.; Blais, L.; Berard, A. Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG., 2007, 114, 1055-1064.
7. Cohen, L.S.; Altshuler, L.L.; Harlow, B.L.; Nonacs, R.; Newport, D.J.; Viguera, A.C.; Suri, R.; Burt, V.K.; Hendrick, V.; Reminick, A.M.; Loughead, A.; Vitonis, A.F.; Stowe, Z.N. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA, 2006, 295, 499-507.
8. Egen-Lappe, V.; Hasford, J. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur. J. Clin. Pharmacol., 2004, 60, 659-666.
9. Malm, H.; Martikainen, J.; Klaukka, T.; Neuvonen, P.J. Prescription drugs during pregnancy and lactation - a Finnish register-based study. Eur. J. Clin. Pharmacol., 2003, 59, 127-133.
10. Andrade, S.E.; Raebel, M.A.; Brown, J.; Lane, K.; Livingston, J.; Boudreau, D.; Rolnick, S.J.; Roblin, D.; Smith, D.H.; Willy, M.E.; Staffa, J.A.; Platt, R. Use of antidepressant medications during pregnancy: a multisite study. Am. J. Obstet. Gynecol., 2008, 198, 194-195.
11. Cooper, W.O.; Willy, M.E.; Pont, S.J.; Ray, W.A. Increasing use of antidepressants in pregnancy. Am. J. Obstet. Gynecol., 2007, 196, 544-545.
12. Garcia-Enguidanos, A.; Calle, M.E.; Valero, J.; Luna, S.; Dominguez-Rojas, V. Risk factors in miscarriage: a review. Eur. J. Obstet. Gynecol. Reprod. Biol., 2002, 102, 111-119.
13. Everett, C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ, 1997, 315, 32-34.
14. Fact Sheets: Spontaneous Abortion (http://www.emcom.ca/health/abortion. shtml). McLaughlin Centre, Institute of Population Health, University of Ottawa, 2009 (GENERIC).
15. Casper, R.C.; Fleisher, B.E.; Lee-Ancajas, J.C.; Gilles, A.; Gaylor, E.; DeBattista, A.; Hoyme, H.E. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J. Pediatr., 2003, 142, 402-408.
16. Griebel, C.P.; Halvorsen, J; Golemon, T.B.; Day, A.A. Management of spontaneous abortion. Am. Fam. Physician, 2005, 72, 1243-1250.
17. Pastuszak, A.; Schick-Boschetto, B.; Zuber, C.; Feldkamp, M.; Pinelli, M.; Sihn, S.; Donnenfeld, A.; McCormack, M.; Leen-Mitchell, M.; Woodland, C.; . Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA, 1993, 269, 2246-2248.
18. Einarson, A.; Fatoye, B.; Sarkar, M.; Lavigne, S.V.; Brochu, J.; Chambers, C.; Mastroiacovo, P.; Addis, A.; Matsui, D.; Schuler, L.; Einarson, T.R.; Koren, G. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am. J. Psychiatry, 2001, 158, 1728-1730.
19. Kulin, N.A.; Pastuszak, A.; Sage, S.R.; Schick-Boschetto, B.; Spivey, G.; Feldkamp, M.; Ormond, K.; Matsui, D.; Stein-Schechman, A.K.; Cook, L.; Brochu, J.; Rieder, M.; Koren, G. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA, 1998, 279, 609-610.
20. Einarson, A.; Bonari, L.; Voyer-Lavigne, S.; Addis, A.; Matsui, D.; Johnson, Y.; Koren, G. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can. J. Psychiatry, 2003, 48, 106-110.
21. Hemels, M.E.; Einarson, A.; Koren, G.; Lanctot, K.L.; Einarson, T.R. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann. Pharmacother., 2005, 39, 803-809.
22. Chambers, C.D.; Johnson, K,A.; Dick, L.M.; Felix, R.J.; Jones, K.L. Birth outcomes in pregnant women taking fluoxetine. N. Engl. J. Med., 1996, 335, 1010-1015.
23. McElhatton, P.R.; Garbis, H.M.; Elefant, E.; Vial, T.; Bellemin, B.; Mastroiacovo, P.; Arnon, J.; Rodriguez-Pinilla, E.; Schaefer, C.; Pexieder, T.; Merlob, P.; Dal, VS. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants: a collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod. Toxicol., 1996, 10, 285-294.
24. Chun-Fai-Chan, B.; Koren, G.; Fayez, I.; Kalra, S.; Voyer-Lavigne, S.; Boshier, A.; Shakir, S.; Einarson, A. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am. J. Obstet. Gynecol., 2005, 192, 932-936.
25. Djulus, J.; Koren G; Einarson, T.R.; Wilton, L.; Shakir, S.; Diav-Citrin, O.; Kennedy, D.; Voyer, L.S.; De, S.M.; Einarson, A. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J. Clin. Psychiatry, 2006, 67, 1280-1284.
26. Nakhai-Pour, H.R.; Broy, P.; Berard, A. Antidepressant medication use during pregnancy and the risk of miscarriage [Abstract]. Can. J. Clin. Pharmacol, 2009, 16, e202-e233.
27. Einarson, A.; Choi, J.; Ginarson, T.R.; Koren G. Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: results from a large prospective database. J. Obstet. Gynaecol. Can., 2009, 31(5), 452-456.
28. th ed., 1996..
29. Patkar, A.A.; Bilal L.; Masand PS. Pharmacotherapy of depression in pregnancy. Ann. Clin. Psychiatry, 2004, 16, 87-100.
30. Simon, G.E.; Cunningham, M.L.; Davis, R.L. Outcomes of prenatal antidepressant exposure. Am. J. Psychiatry, 2002, 159, 2055-2061.
31. Andrade, S.E.; Gurwitz, J.H.; Davis, R.L.; Chan, K.A.; Finkelstein, J.A.; Fortman, K.; McPhillips, H.; Raebel, M.A.; Roblin, D.; Smith, D.H.; Yood, M.U.; Morse, A.N.; Platt, R. Prescription drug use in pregnancy. Am. J. Obstet. Gynecol., 2004, 191, 398-407.
32. Zeskind, P.S.; Stephens, L.E. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics, 2004, 113, 368-375.
33. Lattimore, K.A.; Donn, S.M.; Kaciroti, N.; Kemper, A.R.; Neal, C.R. Jr.; Vazquez, D.M. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J. Perinatol., 2005, 25, 595-604.
34. Costa, L.G.; Steardo, L.; Cuomo, V. Structural effects and neurofunctional sequelae of developmental exposure to psychotherapeutic drugs: experimental and clinical aspects. Pharmacol. Rev., 2004, 56, 103-147.
35. Fleschler, R.; Peskin, M.F. Selective serotonin reuptake inhibitors (SSRIs) in pregnancy: a review. MCN Am. J. Matern. Child Nurs., 2008, 33, 355-361.
36. Rahimi, R.; Nikfar, S.; Abdollahi, M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod. Toxicol., 2006, 22, 571-575.
37. Diav-Citrin, O.; Shechtman, S.; Weinbaum, D. Pregnancy outcome after gestational exposure to paroxetine: a prospective controlled study cohort. [Abstract]. Teratology, 2002, 65, 298.
38. Sivojelezova, A.; Shuhaiber, S.; Sarkissian, L.; Einarson, A.; Koren, G. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am. J. Obstet. Gynecol., 2005, 193, 2004-2009.
39. Diav-Citrin, O.; Shechtman, S.; Weinbaum, D.; Wajnberg, R.; Avgil, M.; Di, G.E.; Clementi, M.; Weber-Schoendorfer, C.; Schaefer, C.; Ornoy, A. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br. J. Clin. Pharmacol., 2008, 66, 695-705.
40. Wisner, K.L.; Gelenberg, A.J.; Leonard, H.; Zarin, D.; Frank, E. Pharmacologic treatment of depression during pregnancy. JAMA, 1999, 282, 1264-1269.
41. Alwan, S.; Reefhuis, J.; Rasmussen, S.A.; Olney, R.S.; Friedman, J.M. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N. Engl. J. Med., 2007, 356, 2684-2692.
42. Bakker, M.K.; Kolling, P.; Van Den Berg, P.B.; De Walle, H.E.; De Jong van den Berg, L.T. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br. J. Clin. Pharmacol., 2008, 65, 600-606.
43. Berard, A.; Ramos, E.; Rey, E.; Blais, L.; St-Andre, M.; Oraichi, D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res. B Dev. Reprod. Toxicol., 2007, 80, 18-27.
44. Casper, R.C.; Fleisher, B.E.; Lee-Ancajas, J.C.; Gilles, A.; Gaylor, E.; DeBattista, A.; Hoyme, H.E. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J. Pediatr., 2003, 142, 402-408.
45. Wichman, C.L.; Fothergill, A.; Moore, K.M.; Lang, T.R.; Heise, R.H. Jr.; Watson, W.J. Recent trends in selective serotonin reuptake inhibitor use in pregnancy. J. Clin. Psychopharmacol., 2008, 28, 714-716.
46. Ryan, D.; Milis, L.; Misri, N. Depression during pregnancy. Can. Fam. Physician, 2005, 51, 1087-1093.
47. Guclu, S.; Gol, M.; Dogan, E.; Saygili, U. Mirtazapine use in resistant hyperemesis gravidarum: report of three cases and review of the literature. Arch. Gynecol. Obstet., 2005, 272, 298-300.
48. Yaris, F.; Kadioglu, M.; Kesim, M.; Ulku, C.; Yaris, E.; Kalyoncu, N.I.; Unsal, M. Newer antidepressants in pregnancy: prospective outcome of a case series. Reprod. Toxicol., 2004, 19, 235-238.
49. Bairy, K.L.; Madhyastha, S.; Ashok, K.P.; Bairy, I.; Malini, S. Developmental and behavioral consequences of prenatal fluoxetine. Pharmacology, 2007, 79, 1-11.
50. Moiseiwitsch, J.R. The role of serotonin and neurotransmitters during craniofacial development. Crit Rev. Oral Biol. Med., 2000, 11, 230-239.
51. Mallmann, E.S.; Ribeiro, M.F.; Spritzer, P.M. Effect of serotonin depletion by p-chlorophenylalanine on serum prolactin levels in estrogen-treated ovariectomized rats: insights concerning the serotoninergic, dopaminergic and opioid systems. Horm. Metab Res., 2001, 33, 337-342.